SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-065509
Filing Date
2022-10-21
Accepted
2022-10-21 16:01:32
Documents
14
Period of Report
2022-10-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea167190-8k_aikidophar.htm   iXBRL 8-K 34052
2 AMENDED AND RESTATED SERVICES AGREEMENT, EFFECTIVE AS OF OCTOBER 17, 2022, BY AN ea167190ex10-1_aikidophar.htm EX-10.1 63842
3 AMENDMENT TO AMENDED AND RESTATED SERVICES AGREEMENT, DATED OCTOBER 19, 2022, BY ea167190ex10-2_aikidophar.htm EX-10.2 8311
  Complete submission text file 0001213900-22-065509.txt   302316

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE aiki-20221012.xsd EX-101.SCH 3239
5 XBRL LABEL FILE aiki-20221012_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE aiki-20221012_pre.xml EX-101.PRE 22367
8 EXTRACTED XBRL INSTANCE DOCUMENT ea167190-8k_aikidophar_htm.xml XML 3593
Mailing Address ONE ROCKEFELLER PLAZA, 11TH FLOOR NEW YORK NY 10020
Business Address ONE ROCKEFELLER PLAZA, 11TH FLOOR NEW YORK NY 10020 347-321-7646
AIkido Pharma Inc. (Filer) CIK: 0000012239 (see all company filings)

IRS No.: 520849320 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-05576 | Film No.: 221323809
SIC: 8731 Services-Commercial Physical & Biological Research